Developer docs
API playgroundTry for free, no card

Search company profiles

CellProthera

Full company profile

uuid0002ecf

Namestring
CellProthera
Legal namestring
CellProthera SAS
Company typeenum
Private
Founded yearint
2008
Descriptiontext

CellProthera SAS is a clinical-stage biotechnology company headquartered in Mulhouse, France, developing autologous CD34+ stem cell therapies for cardiac regeneration following severe acute myocardial infarction. Founded in 2008 by Professor Philippe Hénon, a hematologist with 40+ years of CD34+ research and founder of the Institut de Recherche en Hématologie et Transplantation (IRHT), the company is built around its lead product ProtheraCytes, an autologous cell therapy derived from approximately 200ml of the patient's own blood. CD34+ cells are mobilized, harvested, expanded over 9 days using the proprietary automated StemXpand platform with single-use StemPack kits and StemFeed nutrient media, achieving >90% purity and ~98% viability. The expanded cells are then injected transendocardially into damaged cardiac tissue 4-6 weeks post-MI using the C-CATHez percutaneous catheter, whose IP was acquired from Celyad Oncology in February 2026 for up to €5M plus royalties, giving CellProthera end-to-end control of manufacturing and delivery.

The therapy is being developed for severe AMI patients with persistent left ventricular dysfunction (LVEF <50%), a population with 50% five-year mortality under standard care, and Phase I/IIb EXCELLENT results (49 patients across 13 sites in France and UK) showed a 9% reduction in LV systolic volume index at 6 months, 70% NT-proBNP reduction at 3 months, and heart failure hospitalization rates of 3% versus 19% in control, published in JACC-Heart Failure in 2025. CellProthera is currently preparing for a Phase III pivotal trial with planned expansion to USA, Canada and additional European sites. Manufacturing is performed via a CDMO partnership with CELLforCURE by SEQENS for scale, and CellProthera is expanding into ischemic stroke through a collaboration with Quintessence Biotech and University of South Florida.

The business model is pre-revenue and contingent on regulatory approval; revenue is expected from hospital reimbursement for the autologous cell therapy administered at specialized cardiac catheterization laboratories upon ATMP-classified marketing authorization, with potential early-access pathways in France following Phase II. Go-to-market is enterprise field sales targeting interventional cardiologists and academic medical centers, supported by scientific conference presence (ISCT, ESC Heart Failure), peer-reviewed publications, and earned media in French national outlets. Funding to date totals approximately €28.3M from private investors and family offices, with no institutional VC, PE, or strategic investor disclosed.

Short descriptiontext

CellProthera is a French clinical-stage biotech developing ProtheraCytes, an autologous CD34+ stem cell therapy delivered via its C-CATHez catheter to regenerate cardiac tissue in patients with severe post-myocardial infarction heart failure, currently advancing to Phase III trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMulhouse, France
HQ citystring
Mulhouse
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
autologous cell therapy, cardiac regeneration, stem cell therapy, regenerative medicine, cell therapy manufacturing
Industry5 codes
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAJ
Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAKAFAI
Bone Marrow & Stem Cell Transplant (BMT/HSCT)
SECONDARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
Product category
Cardiac Cell Therapy
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1ProtheraCytes Cell Therapy
TypeOne Time License
Description

Autologous stem cell therapy for post-MI heart failure. Currently in Phase III preparation. Revenue will come from treatment reimbursement upon regulatory approval. Early access pathways possible in France following successful Phase II.

cellprothera.com
2Catheter Sales
TypeLicensing Royalties
Description

Future royalties on net sales of C-CATHez catheter to Celyad Oncology, as part of the acquisition deal terms.

pharmiweb.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1ProtheraCytes
Description

The company's main cell therapy product - expanded autologous CD34+ stem cells for cardiac regeneration

cellprothera.com
+3 more records
Core offering1 text field

CellProthera develops ProtheraCytes, an autologous CD34+ stem cell therapy product derived from a patient's own blood, used to regenerate cardiac tissue following severe acute myocardial infarction. The therapy is administered as a single transendocardial injection 4-6 weeks post-MI using the proprietary C-CATHez catheter, with cells expanded on the company's automated StemXpand manufacturing platform under GMP conditions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 9% reduction in left ventricular systolic volume index at 6 months
+5 more records
Product overview1 text field

CellProthera offers a unified regenerative cardiac therapy platform centered on ProtheraCytes, an autologous CD34+ stem cell therapy. The platform comprises StemXpand (automated cell expansion device) and StemPack (single-use production kits) for manufacturing the cell therapy, combined with the C-CATHez transendocardial catheter for precise cardiac delivery. The therapy is designed as a single administration to regenerate cardiac tissue in patients with severe myocardial infarction, preventing progression to chronic heart failure.

Product and service4 records
1ProtheraCytes
CategoryCell therapy product
Description

Expanded autologous CD34+ stem cell therapy product derived from the patient's own blood. Cells are mobilized, harvested via blood draw (~200ml), expanded for 9 days using the StemXpand automated system (achieving >90% purity and ~98% viability), and injected transendocardially into damaged cardiac tissue 4-6 weeks post-MI to regenerate tissue and prevent chronic heart failure. Designed for severe MI patients with persistent left ventricular dysfunction (LVEF <50%).

2StemXpand
CategoryManufacturing device
Description

Automated cell culture device platform for expanding patient-derived CD34+ stem cells at clinical scale under GMP conditions. Used as part of the integrated ProtheraCytes manufacturing ecosystem.

3StemPack
CategoryManufacturing consumable
Description

Single-use production kit used in conjunction with the StemXpand automated device for clinical-grade, sterile manufacturing of the ProtheraCytes cell therapy.

4C-CATHez Transendocardial Catheter
CategoryDelivery device
Description

Single-use percutaneous catheter with deflectable tip for delivering stem cells (ProtheraCytes) directly into the myocardium. Features an adjustable, retractable beveled fine-gauge needle with predefined penetration depth, controlled tactile feedback, and compatibility with electro-anatomical mapping systems. Designed for transendocardial delivery of therapeutic agents in cardiac procedures.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1Quintessence Biotech
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-04-28
Description

Collaboration to industrialize cell manufacturing processes ahead of stroke clinical trials. CellProthera will use Quintessence's DACSTM flotation-based cell sorting platform to enhance therapeutic purity for ischemic stroke indication.

cellprothera.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-02-12
Description

Acquisition of C-CATHez transendocardial catheter technology including all IP rights for up to €5M in milestone-based payments plus future royalties on net sales. Entirely deferred consideration. Gives CellProthera end-to-end integration from stem cell manufacturing to precise cardiac delivery.

3CELLforCURE (SEQENS)
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

CDMO partnership for Phase III manufacturing and future commercialization of ProtheraCytes cell therapy. CellProthera previously built in-house manufacturing capability out of necessity before 2013, then partnered with CELLforCURE for scale-up. The CEO advocates for developing in-house capabilities when fundraising allows.

technologynetworks.com
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Academic partnership for ischemic stroke research. Collaborating on preclinical data for CD34+ stem cell therapy in acute ischemic stroke. 87% of strokes are ischemic; second leading cause of death globally.

5Pr. David Smadja
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic collaborator who presented Phase I/2b quality of life results with ProtheraCytes at ISTH congress.

cellprothera.com
6Pr. Faïez Zannad
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Professor of Therapeutics at Université de Lorraine, President of EXCELLENT trial steering committee. Presented Phase I/IIb results at Heart Failure 2024 conference.

cellprothera.com
7Pr. Jérôme Roncalli
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Cardiologist at CHU Rangueil, Toulouse, and principal coordinator of EXCELLENT study. Leading investigator for cardiac cell therapy trials.

cellprothera.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing cell therapy (dermato-cel/CAP-1002) for Duchenne muscular dystrophy-associated cardiomyopathy and other cardiac indications. Comparable in cardiac cell therapy focus and clinical stage.

TypeDirect peer
Description

Clinical-stage cell therapy company developing mesenchymal precursor cell therapies for cardiovascular indications including chronic heart failure. Most direct peer in autologous/allogeneic cardiac cell therapy space with late-stage assets.

TypeOthers
Description

Cell therapy manufacturing automation company building closed-system platforms for cell therapy production. Comparable on the cell therapy manufacturing technology side of CellProthera's StemXpand ecosystem.

TypeDirect peer
Description

Cardiac cell therapy company developing the Helix transendocardial delivery catheter platform used to administer cell therapies to the myocardium. Comparable on the cardiac cell delivery side of CellProthera's stack.

TypeBroad incumbent
Description

Bayer-owned clinical-stage company developing iPSC-derived cardiac cell therapies for heart failure. Larger player with deep institutional backing pursuing cardiac regeneration with a pluripotent stem cell platform.

TypeEmerging player
Description

Clinical-stage gene therapy company with cardiac programs targeting inherited and acquired heart disease. Emerging competitor in the broader cardiac regeneration space with a different delivery modality.

TypeDirect peer
Description

Japan-based clinical-stage company developing iPSC-derived cardiomyocyte cell therapy (HS-001) for heart failure. Competes in cardiac regeneration space with a different modality but same therapeutic goal.

TypeOthers
Description

Former cardiac cell therapy developer that divested its C-CATHez catheter IP to CellProthera in February 2026. Strategic counterparty and historical peer in the same cardiac cell delivery category.

TypeEmerging player
Description

Clinical-stage gene therapy company developing cardiac regenerative therapies (e.g., TN-201 for genetic cardiomyopathies). Adjacent modality competing for the same patient population in cardiac regeneration.

10Pluristem Therapeutics
TypeDirect peer
Description

Clinical-stage cell therapy company using placenta-derived allogeneic adherent stromal cells for cardiovascular indications including heart failure. Comparable cell therapy approach targeting post-MI recovery.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CellProthera

Cardiac Cell Therapycellprothera.com

CellProthera is a French clinical-stage biotech developing ProtheraCytes, an autologous CD34+ stem cell therapy delivered via its C-CATHez catheter to regenerate cardiac tissue in patients with severe post-myocardial infarction heart failure, currently advancing to Phase III trials.

What CellProthera does

CellProthera SAS is a clinical-stage biotechnology company headquartered in Mulhouse, France, developing autologous CD34+ stem cell therapies for cardiac regeneration following severe acute myocardial infarction. Founded in 2008 by Professor Philippe Hénon, a hematologist with 40+ years of CD34+ research and founder of the Institut de Recherche en Hématologie et Transplantation (IRHT), the company is built around its lead product ProtheraCytes, an autologous cell therapy derived from approximately 200ml of the patient's own blood. CD34+ cells are mobilized, harvested, expanded over 9 days using the proprietary automated StemXpand platform with single-use StemPack kits and StemFeed nutrient media, achieving >90% purity and ~98% viability. The expanded cells are then injected transendocardially into damaged cardiac tissue 4-6 weeks post-MI using the C-CATHez percutaneous catheter, whose IP was acquired from Celyad Oncology in February 2026 for up to €5M plus royalties, giving CellProthera end-to-end control of manufacturing and delivery.

The therapy is being developed for severe AMI patients with persistent left ventricular dysfunction (LVEF <50%), a population with 50% five-year mortality under standard care, and Phase I/IIb EXCELLENT results (49 patients across 13 sites in France and UK) showed a 9% reduction in LV systolic volume index at 6 months, 70% NT-proBNP reduction at 3 months, and heart failure hospitalization rates of 3% versus 19% in control, published in JACC-Heart Failure in 2025. CellProthera is currently preparing for a Phase III pivotal trial with planned expansion to USA, Canada and additional European sites. Manufacturing is performed via a CDMO partnership with CELLforCURE by SEQENS for scale, and CellProthera is expanding into ischemic stroke through a collaboration with Quintessence Biotech and University of South Florida.

The business model is pre-revenue and contingent on regulatory approval; revenue is expected from hospital reimbursement for the autologous cell therapy administered at specialized cardiac catheterization laboratories upon ATMP-classified marketing authorization, with potential early-access pathways in France following Phase II. Go-to-market is enterprise field sales targeting interventional cardiologists and academic medical centers, supported by scientific conference presence (ISCT, ESC Heart Failure), peer-reviewed publications, and earned media in French national outlets. Funding to date totals approximately €28.3M from private investors and family offices, with no institutional VC, PE, or strategic investor disclosed.

CellProthera firmographics

Firmographics
Name
CellProthera
Legal name
CellProthera SAS
Website
https://cellprothera.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
CellProthera is a French clinical-stage biotech developing ProtheraCytes, an autologous CD34+ stem cell therapy delivered via its C-CATHez catheter to regenerate cardiac tissue in patients with severe post-myocardial infarction heart failure, currently advancing to Phase III trials.
Ownership category
akta.pro rank

CellProthera industry classification

Industry
Product category
Cardiac Cell Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
akta.pro industry
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAJ
Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAKAFAI
Bone Marrow & Stem Cell Transplant (BMT/HSCT)
SECONDARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Autologous cell therapy
  • Cardiac regeneration
  • Stem cell therapy
  • Regenerative medicine
  • Cell therapy manufacturing

Where CellProthera is headquartered

Location

Headquarters

HQ city
Mulhouse
HQ country
France
HQ region
Europe

Offices2 records

Markets served

CellProthera business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. ProtheraCytes Cell Therapy: Autologous stem cell therapy for post-MI heart failure. Currently in Phase III preparation. Revenue will come from treatment reimbursement upon regulatory approval. Early access pathways possible in France following successful Phase II.
  2. Catheter Sales: Future royalties on net sales of C-CATHez catheter to Celyad Oncology, as part of the acquisition deal terms.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

CellProthera product offering

Product offering

Core offering

CellProthera develops ProtheraCytes, an autologous CD34+ stem cell therapy product derived from a patient's own blood, used to regenerate cardiac tissue following severe acute myocardial infarction. The therapy is administered as a single transendocardial injection 4-6 weeks post-MI using the proprietary C-CATHez catheter, with cells expanded on the company's automated StemXpand manufacturing platform under GMP conditions.

Product overview

CellProthera offers a unified regenerative cardiac therapy platform centered on ProtheraCytes, an autologous CD34+ stem cell therapy. The platform comprises StemXpand (automated cell expansion device) and StemPack (single-use production kits) for manufacturing the cell therapy, combined with the C-CATHez transendocardial catheter for precise cardiac delivery. The therapy is designed as a single administration to regenerate cardiac tissue in patients with severe myocardial infarction, preventing progression to chronic heart failure.

Differentiator

Problem solved

Functional benefit

Brands

  • ProtheraCytes: The company's main cell therapy product - expanded autologous CD34+ stem cells for cardiac regeneration
  • StemXpand
  • StemPack
  • StemFeed

Products and services

  • ProtheraCytes Expanded autologous CD34+ stem cell therapy product derived from the patient's own blood. Cells are mobilized, harvested via blood draw (~200ml), expanded for 9 days using the StemXpand automated system (achieving >90% purity and ~98% viability), and injected transendocardially into damaged cardiac tissue 4-6 weeks post-MI to regenerate tissue and prevent chronic heart failure. Designed for severe MI patients with persistent left ventricular dysfunction (LVEF <50%).
  • StemXpand Automated cell culture device platform for expanding patient-derived CD34+ stem cells at clinical scale under GMP conditions. Used as part of the integrated ProtheraCytes manufacturing ecosystem.
  • StemPack Single-use production kit used in conjunction with the StemXpand automated device for clinical-grade, sterile manufacturing of the ProtheraCytes cell therapy.
  • C-CATHez Transendocardial Catheter Single-use percutaneous catheter with deflectable tip for delivering stem cells (ProtheraCytes) directly into the myocardium. Features an adjustable, retractable beveled fine-gauge needle with predefined penetration depth, controlled tactile feedback, and compatibility with electro-anatomical mapping systems. Designed for transendocardial delivery of therapeutic agents in cardiac procedures.

Quantifiable outcome

  • 9% reduction in left ventricular systolic volume index at 6 months
  • +5 more outcomes

Companies that use CellProthera

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles1 record

CellProthera technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

CellProthera partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered major, core and minor.

  • Quintessence BiotechmajorStrategic or Co-development Partner · 28 April 2026Collaboration to industrialize cell manufacturing processes ahead of stroke clinical trials. CellProthera will use Quintessence's DACSTM flotation-based cell sorting platform to enhance therapeutic purity for ischemic stroke indication.
  • Celyad OncologycoreTechnology or Integration · 12 February 2026Acquisition of C-CATHez transendocardial catheter technology including all IP rights for up to €5M in milestone-based payments plus future royalties on net sales. Entirely deferred consideration. Gives CellProthera end-to-end integration from stem cell manufacturing to precise cardiac delivery.
  • CELLforCURE (SEQENS)coreImplementation/ SI/ Consulting PartnerCDMO partnership for Phase III manufacturing and future commercialization of ProtheraCytes cell therapy. CellProthera previously built in-house manufacturing capability out of necessity before 2013, then partnered with CELLforCURE for scale-up. The CEO advocates for developing in-house capabilities when fundraising allows.
  • University of South FloridamajorStrategic or Co-development PartnerAcademic partnership for ischemic stroke research. Collaborating on preclinical data for CD34+ stem cell therapy in acute ischemic stroke. 87% of strokes are ischemic; second leading cause of death globally.
  • Pr. David SmadjaminorStrategic or Co-development PartnerAcademic collaborator who presented Phase I/2b quality of life results with ProtheraCytes at ISTH congress.
  • Pr. Faïez ZannadminorStrategic or Co-development PartnerProfessor of Therapeutics at Université de Lorraine, President of EXCELLENT trial steering committee. Presented Phase I/IIb results at Heart Failure 2024 conference.
  • Pr. Jérôme RoncalliminorStrategic or Co-development PartnerCardiologist at CHU Rangueil, Toulouse, and principal coordinator of EXCELLENT study. Leading investigator for cardiac cell therapy trials.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

CellProthera competitors and assessment

Company assessment

Direct peers

  • Capricor Therapeutics: Clinical-stage biotech developing cell therapy (dermato-cel/CAP-1002) for Duchenne muscular dystrophy-associated cardiomyopathy and other cardiac indications. Comparable in cardiac cell therapy focus and clinical stage.
  • Mesoblast: Clinical-stage cell therapy company developing mesenchymal precursor cell therapies for cardiovascular indications including chronic heart failure. Most direct peer in autologous/allogeneic cardiac cell therapy space with late-stage assets.
  • BioCardia: Cardiac cell therapy company developing the Helix transendocardial delivery catheter platform used to administer cell therapies to the myocardium. Comparable on the cardiac cell delivery side of CellProthera's stack.
  • Heartseed: Japan-based clinical-stage company developing iPSC-derived cardiomyocyte cell therapy (HS-001) for heart failure. Competes in cardiac regeneration space with a different modality but same therapeutic goal.
  • Pluristem Therapeutics: Clinical-stage cell therapy company using placenta-derived allogeneic adherent stromal cells for cardiovascular indications including heart failure. Comparable cell therapy approach targeting post-MI recovery.

Others

  • Cellares: Cell therapy manufacturing automation company building closed-system platforms for cell therapy production. Comparable on the cell therapy manufacturing technology side of CellProthera's StemXpand ecosystem.
  • Celyad Oncology: Former cardiac cell therapy developer that divested its C-CATHez catheter IP to CellProthera in February 2026. Strategic counterparty and historical peer in the same cardiac cell delivery category.

Broad incumbents

  • BlueRock Therapeutics: Bayer-owned clinical-stage company developing iPSC-derived cardiac cell therapies for heart failure. Larger player with deep institutional backing pursuing cardiac regeneration with a pluripotent stem cell platform.

Emerging players

  • Lexeo Therapeutics: Clinical-stage gene therapy company with cardiac programs targeting inherited and acquired heart disease. Emerging competitor in the broader cardiac regeneration space with a different delivery modality.
  • Tenaya Therapeutics: Clinical-stage gene therapy company developing cardiac regenerative therapies (e.g., TN-201 for genetic cardiomyopathies). Adjacent modality competing for the same patient population in cardiac regeneration.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

CellProthera social profiles

Digital presence

CellProthera financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CellProthera leadership team

Management profile

Number of profiles

Profiles9 records

CellProthera funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CellProthera M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CellProthera

What does CellProthera do?

CellProthera develops ProtheraCytes, an autologous CD34+ stem cell therapy product derived from a patient's own blood, used to regenerate cardiac tissue following severe acute myocardial infarction. The therapy is administered as a single transendocardial injection 4-6 weeks post-MI using the proprietary C-CATHez catheter, with cells expanded on the company's automated StemXpand manufacturing platform under GMP conditions.

Is CellProthera a public or private company?

CellProthera is a private company. It is classified as venture growth investor backed and is currently operating.

When was CellProthera founded?

CellProthera was founded in 2008. It employs 11 to 50 people.

Where is CellProthera based?

CellProthera is headquartered in Mulhouse, France, in the Europe region.

How does CellProthera make money?

Two revenue lines are on record. ProtheraCytes Cell Therapy is the primary driver. The others are catheter Sales.

Who are CellProthera's main competitors?

Direct peers on record are Capricor Therapeutics, Mesoblast, BioCardia, Heartseed and Pluristem Therapeutics. Others are Cellares and Celyad Oncology. BlueRock Therapeutics is listed as a broad incumbent. Emerging players are Lexeo Therapeutics and Tenaya Therapeutics.

Does CellProthera have an API?

No public API is recorded for CellProthera.

What industry is CellProthera in?

CellProthera's product category is Cardiac Cell Therapy. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 325414.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Pharma LetterCellProthera inks MoU for ProtheraCytes distribution in JapanCellProthera signed a Memorandum of Understanding with Alfresa Holding to develop and distribute its lead product candidate ProtheraCytes in Japan. The collaboration follows positive EXCELLENT trial results for the autologous CD34+ stem-cell product, which aims to regenerate cardiac tissue after acute myocardial infarction.Pulse 2.0Celyad Oncology Sells C-CATHez Catheter To CellProthera In Deal Worth Up To €5 MillionCelyad Oncology, a Belgium-based biotechnology company, has sold its C-CATHez transendocardial catheter technology to CellProthera in a deal worth up to €5 million. The catheter, designed to deliver stem cells directly into damaged cardiac tissue, will become a cornerstone of CellProthera's therapeutic platform as it advances toward a Phase 3 clinical trial for ischemic heart disease. The transaction consideration is entirely deferred and milestone-based, with future royalties on net sales, and will not affect Celyad Oncology's current cash runway, which is expected to extend into Q3-2026.PharmiWeb.comCellProthera Acquires Full Rights to Transendocardial Catheter Developed by Celyad OncologyCellProthera has acquired full intellectual property rights to the transendocardial catheter originally developed by Celyad Oncology, securing proprietary stem cell delivery technology for its upcoming pivotal Phase 3 clinical trial in heart failure post-myocardial infarction. The transaction, valued at up to €5 million in milestone-based installments plus future royalties on net sales, gives CellProthera end-to-end integration of its value chain from autologous stem cell manufacturing to precise cardiac delivery. The catheter has demonstrated a strong safety and performance profile in over 100 patients and will be central to delivering CellProthera's ProtheraCytes® therapy directly into damaged cardiac tissue.BioProcess InternationalCellProthera acquires catheter for cardiac cell-therapy deliveryCellProthera has acquired a transendocardial catheter developed by Celyad Oncology to enhance its manufacturing and delivery capabilities for its ProtheraCytes cell therapy, which is entering Phase III clinical trials. The company aims to fully own its process from cell production to delivery, with the catheter playing a key role during the upcoming trial and potentially for future therapies.BioProcess InternationalCDMO partnerships: Timing matters for biotech successThe article examines strategic timing considerations for biotech companies deciding when to partner with contract development and manufacturing organizations (CDMOs), using CellProthera as a case study. CellProthera built in-house manufacturing capabilities out of necessity because few CDMOs existed for cell and gene therapies before 2013, then later partnered with CDMO CELLforCURE for Phase III manufacturing and commercialization of its ProtheraCytes cell therapy. Industry perspectives are presented on the trade-offs between early CDMO partnerships and developing internal expertise, with the CEO advocating for in-house capabilities when fundraising allows.Technology NetworksAre We Close to a Stem Cell Therapy for Heart Failure?Dr. Ibon Garitaonandia of CellProthera discusses the company's stem cell therapy ProtheraCytes for treating ischemic heart disease, addressing manufacturing challenges including cell sourcing, cost, and regulatory compliance with Good Manufacturing Practice standards. The company recently reported positive Phase 1/2b trial results demonstrating that transendocardial injection of expanded CD34+ cells was feasible with no unexpected serious adverse events, winning an International Society for Cell & Gene Therapy award for these findings. CellProthera is now partnering with CELLforCURE by SEQENS as its contract development and manufacturing organization to advance a pivotal Phase 3 trial in the USA and Europe.GlobeNewswireCellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes™ for the Treatment of Acute Myocardial InfarctionCellProthera and BioCardia announced successful Phase II trial results for ProtheraCytes in acute myocardial infarction, with plans to continue into Phase III. The trial showed improved segment viability and faster NTproBNP decrease, with no serious adverse events. Both companies expect to enhance delivery capabilities for future studies.GlobeNewswireBioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for PatientsBioCardia and CellProthera amended their agreement to extend the partnership for CellProthera's Phase I/IIb EXCELLENT study of ProtheraCytes. The amendment covers the ongoing study and potential early access commercialization, which could begin in 2024. CellProthera is not required to use BioCardia's delivery system for future efforts.Business Wire BlogFrench biotech CellProthera welcomes three exceptional talents to its executive management teamCellProthera appointed Ibon Garitaonandia as CSO, Henk Streefkerk as CMO, and Olivier Friedrich as CFO. The appointments aim to accelerate its cell therapy platform for heart regeneration and new indications. The company's ProtheraCytes product uses patient-derived stem cells to repair heart tissue.